These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7799105)

  • 1. Are calcium antagonists the best option in elderly hypertensives?
    Forette F; Bert P; Rigaud AS
    J Hypertens Suppl; 1994 Sep; 12(6):S19-23. PubMed ID: 7799105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Differential therapy with calcium antagonists].
    Scholze JE
    Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension in the elderly: the role of calcium antagonists.
    Chalmers JP; Smith SA; Wing LM
    J Cardiovasc Pharmacol; 1988; 12 Suppl 8():S147-55. PubMed ID: 2469896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcium antagonists in the therapy of arterial hypertension in the aged].
    Cordova C; Paradiso M; Leonardo M; Pergolini M; Basili S; Pettirossi G; Coppotelli L
    Clin Ter; 1994 Jun; 144(6):489-99. PubMed ID: 8001333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring].
    Jasiński T; Janicki K; Klima M; Pieniazek W; Bednarz S
    Przegl Lek; 1996; 53(2):73-7. PubMed ID: 8754325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium antagonists in hypertension.
    Bühler FR; Kiowski W
    J Hypertens Suppl; 1987 Aug; 5(3):S3-10. PubMed ID: 3312526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcium inhibitors and arterial hypertension].
    Hugue C; Safar M
    J Mal Vasc; 1989; 14(4):356-9. PubMed ID: 2685164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of arterial hypertension in the elderly. Characteristics of hypertension in aging--use of calcium antagonists].
    Lohmann FW
    Fortschr Med; 1994 Sep; 112(26):350-4. PubMed ID: 7959510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blockers in the treatment of hypertension.
    Raspa RF; Wilson CC
    Am Fam Physician; 1993 Sep; 48(3):461-70. PubMed ID: 8362695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension in elderly--an overview.
    Bhattacharyya A; Das P
    J Indian Med Assoc; 1999 Mar; 97(3):96-101. PubMed ID: 10652909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action and clinical use of calcium antagonists in hypertension.
    Kiowski W; Bolli P; Erne P; Müller FB; Hulthén UL; Bühler FR
    Circulation; 1989 Dec; 80(6 Suppl):IV136-44. PubMed ID: 2557176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment.
    Schiffrin EL
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1192-200. PubMed ID: 15607629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological backgrounds of the drug treatment of hypertension in the elderly.
    Van Zwieten PA
    Blood Press Suppl; 1995; 3():15-20. PubMed ID: 8535537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.